![pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
The stockholders have not assumed any changes at the revenue throughout the the July to September 30 2022 reporting cycle at the company. But, they pay very close attention to BIXTs' operating surplus which was at $0.014225 millions, in the same period.
This could be plainly viewed as promising revelation, for lack of more convalescent references. The improvement from the operating surplus compared to the same period a year before of $-0.547243 millions. This administers many investors assurance related to BIXT.
Throughout the most recent fiscal period, the company has ran the company much more efficiently and slashed the deficit to $-0.203 millions.
Bioxytran Inc is expected to report next financial earnings on April 10, 2023.